HF 7

Drug Profile

HF 7

Latest Information Update: 27 Oct 2004

Price : $50

At a glance

  • Originator CeNeS Pharmaceuticals; Nonindustrial source
  • Class
  • Mechanism of Action Kainic acid receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Stroke

Most Recent Events

  • 27 Oct 2004 Discontinued - Preclinical for Stroke in USA (unspecified route)
  • 12 Sep 2002 No development reported - Preclinical for Stroke in USA (unspecified route)
  • 12 Sep 2002 CeNeS Pharmaceuticals has stopped its research activities and is concentrating on development of late stage candidates.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top